JPS643121A - Remedy for endometriosis - Google Patents

Remedy for endometriosis

Info

Publication number
JPS643121A
JPS643121A JP15802987A JP15802987A JPS643121A JP S643121 A JPS643121 A JP S643121A JP 15802987 A JP15802987 A JP 15802987A JP 15802987 A JP15802987 A JP 15802987A JP S643121 A JPS643121 A JP S643121A
Authority
JP
Japan
Prior art keywords
endometriosis
gonatriene
alkyl
active ingredient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP15802987A
Other languages
Japanese (ja)
Other versions
JPH013121A (en
Inventor
Kazumasa Nitta
Hiroaki Ueno
Norio Hirabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Tanabe Pharma Corp
Original Assignee
Mitsubishi Kasei Corp
Tokyo Tanabe Co Ltd
Mitsubishi Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Kasei Corp, Tokyo Tanabe Co Ltd, Mitsubishi Chemical Industries Ltd filed Critical Mitsubishi Kasei Corp
Priority to JP62-158029A priority Critical patent/JPH013121A/en
Priority claimed from JP62-158029A external-priority patent/JPH013121A/en
Publication of JPS643121A publication Critical patent/JPS643121A/en
Publication of JPH013121A publication Critical patent/JPH013121A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

PURPOSE: To obtain a remedy for endometriosis useful for treating endometriosis, suppressing production and release of pituitary gonadotropin, containing a gonatriene derivative as an active ingredient.
CONSTITUTION: A gonatriene derivative shown by the formula [R is 1W3C alkyl; X is -SOR1 or -SCN (R1 is 1W3C alkyl)] as an active ingredient is pharma ceutically manufactured by a conventional procedure to give the aimed sub stance. The substance can be prepared into powder, granule, tablet, capsule, solution, suppository, emulsion or injection and a dose is about 0.1W50mg per adult daily in the case of oral administration. The compound shown by the formula is obtained by dehydrogenating a diene with dicyanodichlorobenzoqui none and 17α-methylsulfinylmethyl-17β-hydroxy-13β-methyl-gona-4,9,11-tr ien-3-one may be cited as the compound.
COPYRIGHT: (C)1989,JPO&Japio
JP62-158029A 1987-06-25 Endometriosis treatment drug Pending JPH013121A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62-158029A JPH013121A (en) 1987-06-25 Endometriosis treatment drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62-158029A JPH013121A (en) 1987-06-25 Endometriosis treatment drug

Publications (2)

Publication Number Publication Date
JPS643121A true JPS643121A (en) 1989-01-06
JPH013121A JPH013121A (en) 1989-01-06

Family

ID=

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3813B (en) 1990-09-26 1996-03-25 Astra Ab Process for preparing 3-formamido-4-hydroxy-alpha£n£1-methyl-2(p-methoxyphenyl)ethylaminomethyl|benzyl alkohol fumarate (formoterol) and related compounds and derivatives thereof
US5652231A (en) * 1993-11-19 1997-07-29 Mochida Pharmaceutical Co., Ltd. Carcinostatic for hormonotherapy containing dienogest as effective component
WO2013136061A1 (en) 2012-03-12 2013-09-19 Laboratorios Lesvi, S.L. New polymorphic form of a long-acting beta-2 adrenoceptor agonist

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3813B (en) 1990-09-26 1996-03-25 Astra Ab Process for preparing 3-formamido-4-hydroxy-alpha£n£1-methyl-2(p-methoxyphenyl)ethylaminomethyl|benzyl alkohol fumarate (formoterol) and related compounds and derivatives thereof
US5652231A (en) * 1993-11-19 1997-07-29 Mochida Pharmaceutical Co., Ltd. Carcinostatic for hormonotherapy containing dienogest as effective component
WO2013136061A1 (en) 2012-03-12 2013-09-19 Laboratorios Lesvi, S.L. New polymorphic form of a long-acting beta-2 adrenoceptor agonist

Similar Documents

Publication Publication Date Title
JPS5767516A (en) Novel analgesic agent
US4032637A (en) Method of promoting sleep
JPH04295428A (en) Antiallergic agent
JPS57109721A (en) Carcinostatic agent
JPS643121A (en) Remedy for endometriosis
JPS6416721A (en) Antioxidant
JPS6452721A (en) Diabetic remedy containing 7-thiapprostaglandin e1 as active ingredient
CA1139670A (en) Process and composition for reducing blood pressure in animals
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS643122A (en) Remedy for endometriosis
JPS54132239A (en) Anti-tumor agent
JPS56115715A (en) Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative
JPS5675428A (en) Hypoglycemic agent containing procainamide hydrochloride
US3798322A (en) 6 or 7-substituted 4 or 8-(amino-1-methyl-butylamino)quinolines as hypolipidemic agents
JPS6440426A (en) Antitumor agent
JPS5536454A (en) Novel immunosuppressive agent
US3795736A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent
JPS55151511A (en) Antiallergic agent consisting mainly of kynurenic ester derivative
JPS646214A (en) Remedy for ulcerative colonopathy
JPS5569510A (en) Carcinostatic agent
JPS54125663A (en) Carcinostatic agent and novel compound having carcinostatic activity
JPS6425728A (en) Nootropic (noesis improving agent)
JPS57126422A (en) Stabilizing method of lysozyme pharmaceutical
JPS643167B2 (en)
JPS57128625A (en) Carcinostatic